Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Treatment options for high risk early breast cancer

Nadia Harbeck, MD, PhD, Ludwig Maximilians University, Munich, Germany, discusses the treatment landscape for patients with high risk early luminal breast cancer that may have four or more nodes. As per the results from the Phase III monarchE trial (NCT03155997), abemaciclib is recommended for these group of patients and for those with germline BRCA mutations, olaparib is a suitable option. Prof. Harbeck additionally highlights olaparib followed by abemaciclib as a potential treatment strategy for patients with very high risk breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.